Compare Biogen Inc (BIIB) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Wix.Com Ltd — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Wix.Com Ltd trades at $68.86 (market cap $2.79B). The key difference: Biogen Inc is far larger — about 10.8× Wix.Com Ltd's market cap, and Biogen Inc is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| BIIB | WIX | |
|---|---|---|
Market Cap | $30.13B | $2.79B |
Sector | Health | Technology |
52-Week High | $216.63 | $184.24 |
52-Week Low | $128.93 | $40.43 |
Enterprise Value | $37.20B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
WIX stock trades at $68.78, up 10.18% today, with a bullish technical signal from moving averages. Revenue grew to $1.99B in 2025, but net income margin remains negative at -8.19%, and the company faces a securities class action. The P/E ratio is elevated at 62.84, indicating high growth expectations. Recent news highlights the launch of Symphony by Wix, an AI system for SMBs, amidst legal challenges.
The outlook is mixed: strong analyst consensus (65.85% buy rating) and a $79.75 price target suggest upside, but legal risks and negative cash flow in 2025 pose significant headwinds. Investors should weigh growth potential against execution and litigation risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
